Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The date of dealing was September 13, 2023. The form includes details of purchases and sales of the company's 0.1p ordinary shares, with a total of 71,814 shares purchased and 70,216 shares sold. The highest price per unit paid/received was 0.0282, and the lowest price per unit paid/received was 0.0282.

The form does not disclose any cash-settled derivative transactions or stock-settled derivative transactions, including options. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing. Additionally, there are no agreements, arrangements, or understandings relating to options or derivatives.

The disclosure was made on September 14, 2023, and the contact person for further information is Lauren Riley, with a telephone number of 020 7886 2963. The form concludes by stating that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.